Orqis (Lake Forest, CA) is developing devices to prevent or reverse the underlying disease progression of congestive heart failure has closed a $37.4M Series D financing. New investors include Wasatch Advisors, Cross Creek Capital and the Omega Fund along with Boston Scientific and Lighthouse Capital Partners.